Apheresis-inducible cytokine pattern change in severe, genetic dyslipidemias

Cytokine

Volumn 56, Issue 3, 2011, Pages 835-841

  Stefanutti, Claudia ^a   Vivenzio, Antonio ^a   Ferraro, Pietro Manuel ^b   Morozzi, Claudia ^a   Belotherkovsky, Dany ^a  

^a POLICLINICO UMBERTO I   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

Cytokines; Familial hypercholesterolemia; HyperLp(a)lipoproteinemia; Inflammation; LDL apheresis

Indexed keywords

CYTOKINE; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES;

ADULT; AORTA VALVE DISEASE; APHERESIS; ARTICLE; ATHEROGENESIS; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOKINE RESPONSE; DISEASE SEVERITY; DYSLIPIDEMIA; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HYPERLIPOPROTEINEMIA; ISCHEMIC HEART DISEASE; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADULT; BLOOD COMPONENT REMOVAL; CYTOKINES; DEMOGRAPHY; DYSLIPIDEMIAS; FEMALE; HUMANS; MALE; MIDDLE AGED; SAMPLE SIZE;

EID: 81455141339     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2011.08.024     Document Type: Article

References (58)

1. Libby P., Okamoto Y., Rocha V.Z., Folco E. Inflammation in atherosclerosis: transition from theory to practice. Circ J 2010, 74(2):213-220.
2. Ridker P.M., Cannon C.P., Morrow D., Rifai N., Rose L.M., McCabe C.H., et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005, 352:20-28.
3. Packard R.R., Libby P. Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clin Chem 2008, 54(1):24-38.
4. Ridker P.M., Danielson E., Fonseca F.A., Genest J., Gotto A.M., Kastelein J.J., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008, 359(21):2195-2207.
5. Hemphill L.C. Familial hypercholesterolemia: current treatment options and patient selection for low-density lipoprotein apheresis. J Clin Lipidol 2010, 4:346-349.
6. Thompson G.R., Catapano A., Saheb S., Atassi-Dumont M., Barbir M., Eriksson M., et al. Severe hypercholesterolaemia: therapeutic goals and eligibility criteria for LDL apheresis in Europe. Curr Opin Lipidol 2010, 21:492-498.
7. Gu L., Okada Y., Clinton S.K., Gerard C., Sukhova G.K., Libby P., et al. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell 1998, 2:275-281.
8. Schober A., Manka D., von Hundelshausen P., Huo Y., Hanrath P., Sarembock I.J., et al. Deposition of platelet RANTES triggering monocyte recruitment requires P-selectin and is involved in neointima formation after arterial injury. Circulation 2002, 106:1523-1529.
9. Von Hundelshausen P., Weber K.S., Huo Y., Proudfoot A.E., Nelson P.J., Ley K., et al. RANTES deposition by platelets triggers monocyte arrest on inflamed and atherosclerotic endothelium. Circulation 2001, 103:1772-1777.
10. Weber C., Schober A., Zernecke A. Chemokines: key regulators of mononuclear cell recruitment in atherosclerotic vascular disease. Arterioscler Thromb Vasc Biol 2004, 24:1997-2008.
11. Huo Y., Schober A., Forlow S.B., Smith D.F., Hyman M.C., Jung S., et al. Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat Med 2003, 9:961-967.
12. Veillard N.R., Kwak B., Pelli G., Mulhaupt F., James R.W., Proudfoot A.E., et al. Antagonism of RANTES receptors reduces atherosclerotic plaque formation in mice. Circ Res 2004, 94:253-261.
13. Hovland A., Hardersen R., Sexton J., Mollnes T.E., Lappegård K.T. Different inflammatory responses induced by three LDL-lowering apheresis columns. J Clin Apher 2009, 24(6):247-253.
14. Hattori K., Heissig B., Tashiro K., Honjo T., Tateno M., Shieh J.H., et al. Plasma elevation of stromal cell-derived factor-1 induces mobilization of mature and immature hematopoietic progenitor and stem cells. Blood 2001, 97:3354-3360.
15. Bláha M., Krejsek J., Bláha V., Andrýs J., Vokurková D., Malý J., et al. Selectins and monocyte chemotactic peptide as the markers of atherosclerosis activity. Physiol Res 2004, 53(3):273-278.
16. Kobayashi S., Moriya H., Maesato K., Okamoto K., Ohtake T. LDL-apheresis improves peripheral arterial occlusive disease with an implication for anti-inflammatory effects. J Clin Apher 2005, 20(4):239-243.
17. Warner S.J., Auger K.R., Libby P. Human interleukin 1 induces interleukin 1 gene expression in human vascular smooth muscle cells. J Exp Med 1987, 165:1316-1331.
18. Warner S.J., Auger K.R., Libby P. Interleukin 1 induces interleukin 1. II. Recombinant human interleukin 1 induces interleukin 1 production by adult human vascular endothelial cells. J Immunol 1987, 139:1911-1917.
19. Cybulsky M.I., Iiyama K., Li H., Zhu S., Chen M., Iiyama M., et al. A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J Clin Invest 2001, 107:1255-1262.
20. Libby P., Warner S.J., Friedman G.B. Interleukin 1: a mitogen for human vascular smooth muscle cells that induces the release of growth-inhibitory prostanoids. J Clin Invest 1988, 81:487-498.
21. Bodary P.F., Gu S., Shen Y., Hasty A.H., Buckler J.M., Eitzman D.T. Recombinant leptin promotes atherosclerosis and thrombosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2005, 55:119-122.
22. Boisvert W.A., Santiago R., Curtiss L.K., Terkeltaub R.A. A leukocyte homologue of the IL-8 receptor CXCR-2 mediates the accumulation of macrophages in atherosclerotic lesions of LDL receptor-deficient mice. J Clin Invest 1998, 101:353-363.
23. Epstein S.E., Stabile E., Kinnaird T., Lee C.W., Clavijo L., Burnett M.S. Janus phenomenon: the interrelated tradeoffs inherent in therapies designed to enhance collateral formation and those designed to inhibit atherogenesis. Circulation 2004, 109:2826-2831.
24. Luttun A., Tjwa M., Moons L., Wu Y., Angelillo-Scherrer A., Liao F., et al. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med 2002, 8:831-840.
25. Kirii H., Niwa T., Yamada Y., Wada H., Saito K., Iwakura Y., et al. Lack of interleukin-1beta decreases the severity of atherosclerosis in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 2003, 23:656-660.
26. Shimizu K., Shichiri M., Libby P., Lee R.T., Mitchell R.N. Th2-predominant inflammation and blockade of IFN-gamma signaling induce aneurysms in allografted aortas. J Clin Invest 2004, 114:300-308.
27. Liu-Wu Y., Hurt-Camejo E., Wiklund O. Lysophosphatidylcholine induces the production of IL-1beta by human monocytes. Atherosclerosis 1998, 137:351-357.
28. Nishi E., Kume N., Ueno Y., Ochi H., Moriwaki H., Kita T. Lysophosphatidylcholine enhances cytokine-induced interferon gamma expression in human T lymphocytes. Circ Res 1998, 83:508-515.
29. Kume N., Cybulsky M.I., Gimbrone M.A. Lysophosphatidylcholine, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells. J Clin Invest 1992, 90:1138-1144.
30. Zhu Y., Lin J.H., Liao H.L., Verna L., Stemerman M.B. Activation of ICAM-1 promoter by lysophosphatidylcholine: possible involvement of protein tyrosine kinases. Biochim Biophys Acta 1997, 1345:93-98.
31. Takahara N., Kashiwagi A., Maegawa H., Shigeta Y. Lysophosphatidylcholine stimulates the expression and production of MCP-1 by human vascular endothelial cells. Metabolism 1996, 45:559-564.
32. Rong J.X., Berman J.W., Taubman M.B., Fisher E.A. Lysophosphatidylcholine stimulates monocyte chemoattractant protein-1 gene expression in rat aortic smooth muscle cells. Arterioscler Thromb Vasc Biol 2002, 22:1617-1623.
33. Wuttge D.M., Zhou X., Sheikine Y., Wagsater D., Stemme V., Hedin U., et al. CXCL16/SRPSOX is an interferon-gamma-regulated chemokine and scavenger receptor expressed in atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2004, 24:750-755.
34. Rovers C., Netea M.G., De Bont N., Demacker P.N.M., Jacobs C., Kullberg B.J., et al. LPS-induced cytokine production and expression of b2-integrins and CD14 by peripheral blood mononuclear cells of patients with homozygous familial hypercholesterolemia. Atherosclerosis 1998, 141:99-105.
35. Schorle H., Holtschke T., Hunig T., Schimpl A., Horak I. Development and function of T cells in mice rendered interleukin-2 deficient by gene targeting. Nature 1991, 352:621-624.
36. Upadhya S., Mooteri S., Peckham N., Pai R.G. Atherogenic effect of interleukin-2 and antiatherogenic effect of interleukin-2 antibody in apo-E-deficient mice. Angiology 2004, 55:289-294.
37. Simon A.D., Yazdani S., Wang W., Schwartz A., Rabbani L.E. Elevated plasma levels of interleukin-2 and soluble IL-2 receptor in ischemic heart disease. Clin Cardiol 2001, 24:253-256.
38. Barton B.E. The biological effects of interleukin 6. Med Res Rev 1996, 16:87-109.
39. Tilg H., Trehu E., Atkins M.B., Dinarello C.A., Mier J.W. Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood 1994, 83:113-118.
40. Xing Z., Gauldie J., Cox G., Baumann H., Jordana M., Lei X.F., et al. IL-6 is an anti-inflammatory cytokine required for controlling local or systemic acute inflammatory responses. J Clin Invest 1998, 101:311-320.
41. Liao H.S., Matsumoto A., Itakura H., Doi T., Honda M., Kodama T., et al. Transcriptional inhibition by interleukin-6 of the class A macrophage scavenger receptor in macrophages derived from human peripheral monocytes and the THP-1 monocytic cell line. Arterioscler Thromb Vasc Biol 1999, 19:1872-1880.
42. Biasucci L.M., Vitelli A., Liuzzo G., Altamura S., Caligiuri G., Monaco C., et al. Elevated levels of interleukin-6 in unstable angina. Circulation 1996, 94:874-877.
43. Biasucci L.M., Liuzzo G., Fantuzzi G., Caligiuri G., Rebuzzi A.G., Ginnetti F., et al. Increasing levels of interleukin (IL)-1Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of inhospital coronary events. Circulation 1999, 99:2079-2084.
44. Harris T.B., Ferrucci L., Tracy R.P., Corti M.C., Wacholder S., Ettinger W.H., et al. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med 1999, 106:506-512.
45. Blake G.J., Ridker P.M. Novel clinical markers of vascular wall inflammation. Circ Res 2001, 89:736-771.
46. Woods A., Brull D.J., Humphries S.E., Montgomery H.E. Genetics of inflammation and risk of coronary artery disease: the central role of interleukin-6. Eur Heart J 2000, 21:1574-1583.
47. Lindmark E., Diderholm E., Wallentin L., Siegbahn A. Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy. JAMA 2001, 286:2107-2113.
48. Gupta S., Pablo A.M., Jiang X.C., Wang N., Tall A.R., Schindler C. IFN-gamma potentiates atherosclerosis in apoE knock-out mice. J Clin Invest 1997, 99:2752-2761.
49. Buono C., Come C.E., Stavrakis G., Maguire G.F., Connelly P.W., Lichtman A.H. Influence of interferon-gamma on the extent and phenotype of diet-induced atherosclerosis in the LDLR-deficient mouse. Arterioscler Thromb Vasc Biol 2003, 23:454-460.
50. Hansson G.K., Holm J., Holm S., Fotev Z., Hedrich H.J., Fingerle J. Lymphocytes-t inhibit the vascular response to injury. Proc Natl Acad Sci USA 1991, 88:10530-10534.
51. Hansson G.K., Holm J., Jonasson L. Detection of activated T lymphocytes in the human atherosclerotic plaque. Am J Pathol 1989, 135:169-175.
52. Warner S.J., Libby P. Human vascular smooth muscle cells. Target for and source of tumor necrosis factor. J Immunol 1989, 142:100-109.
53. Yokota T., Shimokado K., Kosaka C., Sasaguri T., Masuda J., Ogata J. Mitogenic activity of interferon gamma on growth-arrested human vascular smooth muscle cells. Arterioscler Thromb 1992, 12:1393-1401.
54. Minami M., Kume N., Shimaoka T., Kataoka H., Hayashida K., Akiyama Y., et al. A novel cell-surface scavenger receptor for phosphatidylserine and oxidized LDL in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2001, 21:1796-1800.
55. Christen S., Thomas S.R., Garner B., Stocker R. Inhibition by interferon-gamma of human mononuclear cell-mediated low density lipoprotein oxidation. Participation of tryptophan metabolism along the kynurenine pathway. J Clin Invest 1994, 93:2149-2158.
56. Fong L.G., Albert T.S.E., Hom S.E. Inhibition of the macrophage-induced oxidation of low density lipoprotein by interferongamma. J Lipid Res 1994, 35:893-904.
57. Brand K., Mackman N., Curtiss L.K. Interferon-gamma inhibits macrophage apolipoprotein E production by posttranslational mechanisms. J Clin Invest 1993, 91:2031-2039.
58. Panousis C.G., Evans G., Zuckerman S.H. TGF-beta increases cholesterol efflux and ABC-1 expression in macrophage-derived foam cells: opposing the effects of IFN-gamma. J Lipid Res 2001, 42:856-863.